Stress, medications, global travel and an imbalanced diet are having an increasingly adverse effect on the health of the population derived from weakened immune systems. This manifests itself in the occurrence of serious ailments such as acute infectious diarrhoea (AID), ulcerative colitis (UC), traveller’s diarrhea, etc.

QUALVIVO bacterial system platform was developed as part of the project “The Development of a Next Generation Probiotic Supplement for Treatment and Prevention of Antibiotic Associated Diarrhoea”. The Qualvivo project has recieved funding from the EC FWP 7 for SME.

The Qualvivo bacterial system allows high efficacy in infection prevention and interception.

The Qualvivo bacterial system concept is patent protected.


Antibiotic drugs, which are necessary to treat many infections of the body, have the undesirable side-effect of disturbing the microflora by killing many of these indigenous microbes. Such disturbance may lead to diarrhoea (known as antibiotic-associated diarrhoea or AAD). The proccess by which such diarrhoea develops, is that pathogens which were previously suppressed to small numbers by the microflora, suddenly have an opportunity to flourish.

One pathogen in particular, Clostridium difficile, is especially troublesome in such situations, and will grow to high numbers and cause severe infection and inflammation in the large intestine. This infection causes the patient to develop colitis, with symptoms of bloody diarrhoea, pain in the lower abdomen, and often fever. The colitis may develop further into pseudomembranous colitis, which is a life-threatening condition. C. difficile colitis can spread from patient to patient in hospital wards, especially those containing severely-ill or elderly patients, because antibiotics are used commonly among such groups. In the Western world, there is an increased prevalence of strains of C. difficile that have gained resistance to the majority of antibiotics used to treat patients. These multiply-resistant strains are known colloquially as ‘super-bugs’. AAD thus constitutes a growing problem, with serious consequences.

Over the centuries, populations with a high consumption of fermented food have been  recognized as having a low rate of intestinal disturbancies. Fermented food is food that has been improved by the use of microbes, especially those that secrete lactic acid. Recognition of the benefits of fermented food has encouraged a market for “healthy food”, such as products containing microorganisms which, when ingested in sufficient amounts, confer benefits to your health.

The pathogen C.diff is the 10th most common principal discharge diagnoses (among the gastrointestinal diagnoses) in the USA with an annual aggregate cost of USD 1,119,213,000 and a growth in mortality.

The increase and spread of antimicrobial resistance (AMR) is a rapidly growing global problem, following the antibiotic medication and over-consumption of antibiotics.

The EU and USA has establish a joint task force to combat antimicrobial resistance – “The EU and the US will, along with the World Health Organisation, take the lead in dealing with the disastrous situation we find ourselves in.” 19 Member states have joined forces in the Joint Programme Initiative on Antimicrobial Resistance (JPIAMR) to coordinate the research, in order to allow greater impact and avoid duplication.


We tailor-make a mixture of probiotic strains and prebiotic substances, into a ‘synbiotic’ preparation. We select strains that can adhere to the intestine (i.e. stay in the intestine and exert beneficial effects) even after being exposed to acid and bile.

We have ensured that these “good” properties are maintained when different strains are grown together, and in the presence of prebiotics and pathogens such as for example C. difficile. This has been done in laboratory tests, but also in experiments with mice and in an artificial gut.

In the QV prototype product the strains have been tested for their ability to suppress growth of the pathogen C. difficile.

The Qualvivo bacterial system concept allows high efficacy in bacterial infection prevention and interception. The Qualvivo bacterial system is a much needed complement to antibiotics with the increase  and spread of antimicrobial resistance (AMR).

The Qualvivo bacterial system concept is patent protected.

Interested in partnering and more information

Interested in partnering, publications and more information –
Contact  Mr. Mats Wallstrom.